Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Keros Therapeutics logo — Keros is dedicated to the discovery and development of novel...

Keros Therapeutics

Keros is dedicated to the discovery and development of novel therapeutics for multiple disorders.

Founded 2016 United States Lexington, United States 123 employees IPO Total: $379.50M Biotechnology, Health Care +2

General Information

Company Name Keros Therapeutics
Founded Year 2016
Location United States Lexington, United States
Employees 123
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage IPO
Business Model B2B, B2C, B2D
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Keros Therapeutics. To contact Keros Therapeutics, visit kerostx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Keros Therapeutics compare?

A PDF of Keros Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Keros Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Keros Therapeutics

Keros Therapeutics, founded in 2016, is a biotechnology innovator headquartered in the United States and operates across several key industries, including Biotechnology, Health Care, Health and Wellness, and Pharmaceutical.

The company is dedicated to the discovery and development of novel therapeutics aimed at treating a variety of disorders linked to the dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. It seeks to revolutionize treatment protocols, thus fulfilling its mission to innovate therapies and shift existing medical paradigms.

In its most recent financial chapter, Keros Therapeutics secured a significant $140.00M post-IPO equity investment on 03 January 2024, an impressive milestone signaling strong investor confidence in its potential to deliver groundbreaking solutions within its target therapeutics domain.

Business keywords: biopharmaceutical, therapeutics development, TGF-ß signaling, hematologic disorders, musculoskeletal disorders, clinical-stage company, cytopenias treatment, myelodysplastic syndromes, myelofibrosis, anemia treatment, thrombocytopenia, hepcidin regulation, fibrodysplasia ossificans progressiva, osteoporosis treatment, pulmonary arterial hypertension

Services & Products

Development of novel therapeutics
Modulation of TGF-beta signaling
Clinical trials for drug candidates
Hematology and neuromuscular franchises

Target Customers

Patients with TGF-beta related disorders Healthcare professionals Research institutions Neuromuscular disorder specialists

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity $140.00M -
01 Jan 2024
Post-IPO Equity $149.50M -
01 Nov 2020
Series C $56.00M -
01 Apr 2020
Series B $23.00M 3
Global Health Investment Fund Partners Innovation Fund
Global Health Investment Fund, Partners Innovation Fund +1
01 Jan 2019
Series A $11.00M 1
Pontifax
Pontifax
01 Nov 2017
Spinout Undisclosed 1
University Of Houston
01 Jan 2015

Keros Therapeutics Alternatives & Competitors

View All Alternatives
Keros Therapeutics vs
Endeavor BioMedicines
Endeavor BioMedicines United States

Boldly pursuing development of transformational medicines that may restore hope for patients with in...

Series C
52 employees
Biotechnology, Health Care
Keros Therapeutics vs
Lumos Pharma
Lumos Pharma United States

Transforming Lives with Rare Focus

Series B
47 employees
Biopharma, Biotechnology
Keros Therapeutics vs
Geron Corporation
Geron Corporation

Changing lives by changing the course of blood cancer.

Post-IPO Equity
356 employees
Biopharma, Biotechnology
Compare Keros Therapeutics vs Geron Corporation
Also compare with: Keros Therapeutics vs OrsoBio OrsoBio View all alternatives

FAQ About Keros Therapeutics

Keros is dedicated to the discovery and development of novel therapeutics for multiple disorders.
Keros Therapeutics was founded in 2016.
Keros Therapeutics is headquartered in Lexington, United States.
Keros Therapeutics operates in Biotechnology, Health Care, Health and Wellness and Pharmaceutical. Its work centres on biopharmaceutical, therapeutics development, TGF-ß signaling and hematologic disorders. Its customers include Patients with TGF-beta related disorders, Healthcare professionals and Research institutions.
Keros Therapeutics has a B2B, B2C and B2D business model. Its revenue comes from Licensing and Product Sales.
Keros Therapeutics has approximately 123 employees.
Keros Therapeutics has completed 6 funding rounds, raising a total of $379.50M. The latest funding stage is IPO.
Keros Therapeutics offers: Development of novel therapeutics, Modulation of TGF-beta signaling, Clinical trials for drug candidates, Hematology and neuromuscular franchises.
Top alternatives and competitors to Keros Therapeutics include Endeavor BioMedicines, Lumos Pharma, Geron Corporation, OrsoBio, Oncotelic. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Keros Therapeutics and Endeavor BioMedicines are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Keros Therapeutics, https://bouncewatch.com/company/keros-therapeutics, updated 18 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout